We retrospectively analysed the outcome of voluntary unrelated donor (VUD)-SCT in 56 patients after conditioning without or with ATG. All received partially lymphocyte-depleted grafts. Four of 17 patients (24%) who were not given ATG rejected their grafts, as did one of 33 (3%) conditioned with ATG (P ¼ 0.02). The incidences of acute graft-versus-host disease grade III/ IV were 29 and 6%, respectively (P ¼ 0.02), and probabilities of 1-year transplant-related mortality were 64% (95% CI, 44-84%) and 27% (95% CI, 12-42%), respectively (P ¼ 0.004). Projected at 3 years, probability of survival was 18% (95% CI, 2-34%) after conditioning without ATG and 60% (95% CI, 43-70%) after conditioning with ATG (P ¼ 0.002). Probabilities of disease-free survival (DFS) were 18% (95% CI, 2-34%) and 45% (95% CI, 27-63%), respectively (P ¼ 0.005). Patients who did not receive ATG had a probability of current DFS of 18% (95% CI, 3-34%) and this was 60% (95% CI, 43-77%) for the patients conditioned with ATG (Po0.001). We conclude that the addition of ATG to the conditioning regimen is associated with a significantly more favourable outcome in recipients of partially T-cell-depleted grafts from VUDs.
Allogeneic stem cell transplantation is a curative treatment modality for a number of malignant diseases and bone marrow failure. [1] [2] [3] However, only 25% of patients have an HLA genotypically identical brother or sister. Transplantation with grafts from other donors is associated with more morbidity and mortality due to rejection, (acute and chronic) graft-versus-host disease (GVHD), and opportunistic infections. 4 Apart from GVHD, these complications occur more frequently in recipients of (partially) lymphocyte depleted grafts. 5, 6 In March 1990, we started a transplant programme with grafts from voluntary unrelated donors (VUDs). All grafts were partially depleted of lymphocytes. In order to improve results, we added ATG to our conditioning regimen. Furthermore, we introduced a cytotoxic T-lymphocyte precursor frequency (CTLp-f) assay as a criterion for donor selection.
We describe the results of transplantation and show that in our patients, conditioning with the addition of ATG was associated with a significantly more favourable outcome.
Patients and methods

Patients
The 56 consecutive patients were transplanted for hematologic malignancies with stem cells from HLA-A, -B, -DRB, and -DQB identical voluntary unrelated donors between March 1990 and October 2002. Donors were recruited through the Bone Marrow Donorbank Europdonor Nijmegen. The first patient was conditioned with the addition of ATG but died from resistant herpes simplex virus infection, and for that reason the following 21 patients were conditioned without the addition of ATG. However, six of these 21 patients (29%) suffered from take failure or rejection, and from 1997 onwards ATG was again added to the conditioning regimen of all but one of the next 34 patients. The only patient not given ATG from 1997 onwards was a patient transplanted for Hodgkin's disease. In summary, there were 22 patients conditioned without ATG and 34 patients conditioned with the addition of ATG. Patients were divided into good risk and bad risk. In our patients, good-risk indications were transplant for refractory anemia, refractory anemia with an excess of blasts in transformation (RAEB-t) in first complete remission and CML-CP1. Bad-risk indications were: AML not in CR1, ALL not in CR1, RAEB-t not in CR1, CML not in CP1, CLL, NHL not in CR1, Hodgkin's disease, and MM. In Table 1 , the number of patients with good-risk features is given for patients transplanted with and without ATG.
Patients conditioned without ATG were given total body irradiation (TBI) (12 Gy) with cyclophosphamide (120 mg/ kg body weight; no. ¼ 8), TBI (9 Gy), cyclophosphamide (120 mg/kg body weight) plus idarubicin (42 mg/m 2 , no. ¼ 4), and in nine patients conditioning consisted of cyclophosphamide (120 mg/kg body weight), TBI (9 Gy), and total lymphoid irradiation (TLI, 12 Gy, n ¼ 9). The patient transplanted for relapsed Hodgkin's disease was conditioned with TLI, 2 Â 2 Gy for each of three consecutive days (total dose 12 Gy) plus cyclophosphamide (200 mg/kg body weight).
In all, 34 patients were conditioned with the addition of ATG (Thymoglobulin, Sangstat, Lyon, France). The first 11 were given 4 mg/kg body weight on each of 4 consecutive days (total dose 16 mg/kg) and the next 23 patients received 2 mg/kg on each of 4 consecutive days (total dose 8 mg/kg). Apart from ATG, patients were given cyclophosphamide (120 mg/kg body weight) and TBI (9 Gy, n ¼ 31) or busulphan (n ¼ 3). Patient and donor characteristics and indications for transplantation are given in Table 1 .
In all cases, grafts were obtained from bone marrow. Grafts were preseparated to eliminate erythrocytes and granulocytes, by gradient centrifugation using Percoll or PureCell separation medium (MediCult, Jyllinge, Denmark). In total, 47 grafts were partially depleted of T-and B-lymphocytes by using counterflow centrifugation elutriation (CCE) 7 and nine by immunomagnetic negative selection with CD2 and CD19 using the Isolex 300i (Nexell-Baxter, Healthcare, Deerfield, IL, USA). After CCE, the number of T-lymphocytes given within the graft varied from 0.3 to 0.7 (median, 0.7) Â 10 6 per kg body weight of the recipient, and after selection with the Isolex 300i a fixed number of 0.5 Â 10 6 T-lymphocytes was given. Patients were managed in single rooms with air filtered under positive pressure. They received selective oral gut decontamination consisting of ciprofloxacin 500 mg orally twice daily, as well as cotrimoxazole for Pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis of herpes infection. Specific prophylaxis for cytomegalovirus (CMV) was not given. Blood products were not selected for CMV negativity but depleted of leucocytes.
HLA typing and functional matching of donor and recipients
Minimal matching criteria were HLA-A and -B identity at the serological split level, and HLA-DRB and -DQB identity at the four-digit level. Serological HLA-A and -B typing was performed by standard microcytotoxicity assays (broad antigens and splits). In addition, samples were typed at the DNA level by PCR-based techniques. From 1995 Conditioning with the addition of ATG A Schattenberg et al onwards, a PCR-SSP technique was applied for highresolution typing of HLA-A, -B, -DRB3, -DRB4, -DRB5, and -DQB, (Dynal, Oslo, Norway or Pel-Freeze, Brown Deer, USA). Tests were performed according to the manufacturer's instructions. DRB1 high-resolution typing was by Sequence Based Typing on the 'ALF Express' (Pharmacia, Uppsala, Sweden) using the manufacturer's protocol with local adjustments. Recipient and donor were considered HLA-A, -B, -DR, and -DQ identical at the time of transplantation, by the methods currently in use. In several recipient-donor pairs, retrospective subtyping revealed HLA-A, -B, -DRB or -DQB subtype mismatches (five times in patients conditioned without ATG and four times in patients conditioned with ATG). Retrospective typing for HLA-Cw by PCR-SSP revealed five mismatches in patients conditioned without ATG and eight mismatches in patients conditioned with ATG. From October 1998 onwards and in 26 patient-donor combinations, CTLp-fs were determined in the graftversus-host direction from a single limiting dilution assay, as described previously. 8, 9 CTLfs outcome was considered positive when the precursor frequency was 10 or more per 10 6 PBMCs. From the introduction of the CTLP assay onwards, patient-donor combinations with a CTLp-f of 410 per 10 6 PBMCs were considered not suitable for transplantation.
Prospectively (no. ¼ 25) and retrospectively (no. ¼ 8), CTLp-fs were analysed in 33 of the 34 patients conditioned with ATG, and all were negative. Prospectively (no. ¼ 1) and retrospectively (no. ¼ 16), CTLp-fs were analysed in 17 of 22 patients who were not conditioned with ATG. CTPp frequencies were negative in 11 and positive in six patientdonor combinations.
Immunoprophylaxis after transplantation
All patients received cyclosporin A (CsA) 3 mg/kg body weight/day by continuous intravenous infusion from days À1 to þ 14, followed by 2 mg/kg body weight/day by continuous intravenous infusion on to day 21. CsA levels were assessed twice weekly to obtain a level between 200 and 400 ng/ml. After day 21, CsA was given orally at a dose of 6 mg/kg body weight/day until 12 weeks after transplantation. The aim was to reach a trough level between 200 and 400 ng/ml. Beyond 12 weeks, CsA was gradually tapered off and discontinued at 16 weeks.
Definitions
Acute GVHD was classified as grade I-IV according to Glucksberg et al 10 and chronic GVHD as limited or extensive following the Shulman criteria. 11 The day of engraftment was defined as the first of 3 consecutive days on which leucocytes were X1.0 Â 10 9 /l. In patients with take failure (primary rejection), leucocytes never reached 1.0 Â 10 9 /l. Rejection was described as the disappearance of leucocytes after engraftment, and disappearance of bone marrow cellularity was confirmed by histologic examination. Transplant-related mortality (TRM) was defined as death while in continuous complete remission. Relapse was defined as the reappearance of all clinical features and laboratory findings compatible with the underlying disease. In CML patients relapse was defined as molecular and/or cytogenetic and/or hematological relapse. The definition of current disease-free survival (DFS) was DFS at the end of follow-up and included patients who entered complete remission after the infusion of lymphocytes (DLI) from the original donor.
12 Follow-up ended with death, or on 1 January 2003. The median follow-up for the patients conditioned without ATG was 5 months (range, 0-149), and this was 21 months (range, 1-71) for the patients who were conditioned with the addition of ATG.
Statistics
The w 2 test was used for comparison of categorical variables. The Mann-Whitney U-test was used to compare continuous variables. The probabilities of TRM, relapse, survival, DFS, and current DFS were calculated using the Kaplan-Meier method. Differences in probabilities were calculated using the log-rank test. Calculations were made using the Statistica 6.0 programme (StatSoft, Inc., Tulsa, OK, USA). P-values o0.05 were considered significant.
Results
Take failure and rejection
Of the 22 patients, 20 (91%) conditioned without ATG had a follow-up of 414 days. Three patients (16%) did not engraft and four of the remaining 17 patients (24%) rejected their grafts. All 34 patients conditioned with ATG had a follow-up of 414 days. One patient did not engraft (3%) and one of the remaining 33 recipients rejected the graft (3%). The incidence of take failure did not differ significantly, but the incidence of rejection was significantly higher in the patients who did not receive ATG (P ¼ 0.02).
Acute and chronic GVHD
Acute GVHD grade III-IV occurred in five of the 17 evaluable patients (29%) who were not conditioned with ATG and in two of the 33 (6%) evaluable patients after conditioning with ATG (P ¼ 0.02). The incidence of extensive chronic GVHD was 20% in the patients conditioned without ATG and 11% in the patients after conditioning with ATG. The incidences of extensive chronic GVHD did not differ significantly between the two groups.
TRM and causes of death
Of 22 patients, 18 (82%) not conditioned with ATG died and 13 of 34 patients (38%) died after conditioning with the addition of ATG (P ¼ 0.001). The probability of TRM at 12 months after SCT was 64% (95% CI, 44-84%) for the patients not conditioned with ATG and 27% (95% CI, 12-42%) for the patients who were given ATG as part of the conditioning regimen (P ¼ 0.004). Principal causes of death are given in Table 2 .
Conditioning with the addition of ATG A Schattenberg et al
Probability of relapse, survival, DFS, and current DFS
The probability of relapse projected at 3 years after SCT was 44% (95% CI, 11-77%) for the patients who were not given ATG and this was 38% (95% CI, 17-59%) for the patients after conditioning with ATG (P40.05, Figure 1 ). The probability of survival projected at 3 years after SCT was 18% (95% CI, 2-34%) for the patients conditioned without ATG and 60% (95% CI, 43-77%) for the patients who were conditioned with ATG (P ¼ 0.002, Figure 2 ). The patients conditioned without ATG had a probability of DFS (projected at 3 years after transplantation) of 18% (95% CI, 2-34%) and this was 45% (95% CI, 27-63%) for the patients after conditioning with ATG (P ¼ 0.005, Figure 3 ). Four patients with CML who relapsed entered second complete remission after DLI. The probability of current DFS projected at the end of follow-up was 18% (95% CI, 2-34%) and 60% (95% CI, 43-77%) for the patients conditioned without and with the addition of ATG, respectively (Po0.001, Figure 4 ).
Subanalysis on patients transplanted with grafts from donors with negative CTLp-fs
Retrospectively, CTLp-fs could be analysed in 24 of 30 patients whose donors were not prospectively selected on Conditioning with the addition of ATG A Schattenberg et al the basis of CTLp-f. In these 24 patient-donor combinations, CTLp-fs were negative in 18 and positive in six cases. The six patients with CTLp-positive frequencies were all conditioned without the addition of ATG and all but one died (two from take failure, two from acute GVHD, and one from relapse). Retrospectively (n ¼ 18) or prospectively (n ¼ 26), CTLp-fs were negative in 44 of 56 patient-donor pairs. Of these 44 patients, 33 were conditioned with ATG and 11 were not given ATG. Outcomes of patients transplanted with marrow grafts from CTLp-f-negative donors are given in Table 3 . Despite the significantly higher number of T cells infused, patients conditioned with the addition of ATG had lower incidences of acute GVHD grade III/IV and extensive chronic GVHD, although these differences were not statistically significant. The probability of TRM was significantly lower in patients transplanted with the addition of ATG and probabilities of survival and current DFS were significantly higher.
Discussion
The first patient we transplanted with a partially depleted graft from a voluntary unrelated donor was conditioned with cyclophosphamide, ATG, and TBI. He developed therapy-resistant herpes simplex virus infection and died. We could not exclude an association between the conditioning with the addition of ATG and the use of partially lymphocyte-depleted grafts on this fatal course and decided to use our standard conditioning regimen for HLAidentical SIBS with or without the addition of idarubicin. 13 However, this regimen was disappointing in transplants with grafts from voluntary unrelated donors, since five of 12 patients (42%) suffered from take failure or rejection. In a modification of Soiffer et al, 14 conditioning was changed to TBI, TLI, and cyclophosphamide. We used this conditioning regimen on 10 patients and rejection occurred in only one. However, nine patients died from GVHD and/ or infections. After we changed our conditioning regimen to TBI (or busulphan), cyclophosphamide, and ATG, take failure and rejection occurred in only two of 34 patients. TRM decreased significantly and probabilities of survival, DFS, and current DFS improved significantly. The results of patients conditioned with the addition of ATG compare favourably with the outcomes given in the literature, especially taking into consideration the poor-risk features of almost 50% of our patients. In unrelated donor transplants for CML (65% of patients were transplanted in CP1 and 81% of donors were serologically matched for HLA-A, -B, and -DR), McGlave et al 15 found take failures in 9.9% and rejections in 6.6% of transplants. Acute GVHD grade III/IV was observed in 33% (95% CI, 30-36%) and extensive chronic GVHD occurred in 60% (95% CI, 56-63%) at 2 years. In a subset of 157 young (less than 35 years) chronic phase patients transplanted within 1 year of diagnosis with HLA matched donors, DFS at 3 years was 63% (95% CI, 53-73%). In all, 23% of patients received marrow treated ex vivo to deplete T-lymphocytes, Table 3 Characteristics of patients and donors and outcome after transplantation with grafts from VUDs with negative CTLp frequencies that were partially depleted of lymphocytes: comparison of patients conditioned without or with the addition of ATG Our patients conditioned without ATG had more take failures and more rejections than the patients who were given ATG, caused by the additional and long-lasting immunosuppression of the host by ATG. Although the patients who were given ATG received significantly more T cells with the graft, they had a lower incidence of acute GVHD grade III/IV and a lower incidence of extensive chronic GVHD. Also in the recipients of CTLp-f-negative grafts, conditioning with the addition of ATG was associated with less severe acute and chronic GVHD. Pretransplant ATG administration may have reduced the risk of acute and chronic GVHD as reported by Bacigalupo et al. 17 The addition of ATG was not associated with a higher relapse rate and TRM was significantly lower in the ATG-conditioned patients. We confirm the observation of Remberger et al, 18 who found that thymoglobulin during conditioning may reduce nonrelapse mortality after unrelated marrow transplantation, although their observation was carried out in recipients of T-cell-repleted grafts.
Two patients died from EBV-related post transplantation lymphoproliferative disorders (PTLD). Both were conditioned with ATG. The addition of ATG to the conditioning regimen, especially in recipients of partially T-cell-depleted grafts is associated with a higher incidence of PTLD. 19 Recently, we introduced a PCR assay for quantitative detection of EBV-DNA in plasma at weekly intervals, and according to Van Esser et al 20 we are using rituximab as pre-emptive therapy in patients with viral reactivation of at least 1000 geq/ml.
Restrospectively, subtype mismatches were found in five of 22 patients (23%) who were conditioned without ATG and in four of 34 recipients (12%) who were conditioned with ATG (P40.05). HLA-Cw mismatches were found in five of 22 patients (23%) who were not conditioned with ATG and in eight of 34 patients (24%) who were given ATG (P40.05). These HLA-A, -B, -DR, or -DQB subtype mismatches did not differ significantly between the two groups. We could not analyse the impact of the addition of ATG on outcome in recipients of CTLp-f-positive donors since all recipients of CTLp-f-positive grafts were conditioned without the addition of ATG. However, in recipients of CTLp-f-negative grafts, the outcome after conditioning with the addition of ATG remained more favourable than without the addition of ATG. We conclude that in our patients the addition of ATG to the conditioning regimen is significantly associated with a favourable outcome in recipients of partially T-cell-depleted grafts from unrelated donors.
